
    
      PANTHER is a registered phase I/phase II trial in patients with recurrent or metastatic
      colorectal cancer.

      The phase II part of the study will be a single arm trial. Patients will receive AZD8931 (an
      EGFR/ERBB inhibitor) in combination with FOLinic acid, Fluorouracil and IRInotecan (FOLFIRI),
      Treatment will be given in two-weekly cycles. Phase II's primary objective is to evaluate the
      Best overall response
    
  